Beijing grants first COVID-19 vaccine patent to CanSino Biologics Inc

In a significant development, Chinese vaccine specialist CanSino Biologics Inc has been approved by Beijing to produce its COVID-19 vaccine candidate Ad5-nCOV, said a report from the state media citing documents from the China’s intellectual property regulator.

This is the first COVID-19 vaccine patent granted by China, said state-owned newspaper People’s Daily in a report.

The report cited documents published by China’s National Intellectual Property Administration stating that the patent was issued on August 11.

Incidentally, earlier this month, Saudi Arabia stated, it plans on commencing Phase III clinical trials of the CanSino vaccine.

CanSino is also reportedly in talks with Russia, Chile and Brazil to launch Phase III trials in those countries.

With the news reaching the market, CanSino’s Hong Kong shares surged by 14% in Monday’s morning session.

Categories: Creativity, Entrepreneurship, HR & Organization, Regulations & Legal, Strategy

Tags: , , , , , , , , , , , , , , , , , , , , , , , ,

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: